We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+56.7%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$347M
AUM Growth
+$107M
Cap. Flow
+$4.3M
Cap. Flow %
1.24%
Top 10 Hldgs %
48.52%
Holding
95
New
16
Increased
11
Reduced
34
Closed
8

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$7.34M
2
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$6.6M
3
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$6.16M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$5.48M
5
LQDA icon
Liquidia Corp
LQDA
+$4.17M

Top Sells

Rank Stock Value
1
ATRC icon
AtriCure
ATRC
+$4.64M
2
DXCM icon
DexCom
DXCM
+$4.37M
3
CRBP icon
Corbus Pharmaceuticals
CRBP
+$4.31M
4
CGEN icon
Compugen
CGEN
+$3.47M
5
ASND icon
Ascendis Pharma A/S
ASND
+$2.68M

Sector Composition

Rank Sector Weight
1 Healthcare 88.26%
2 Financials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NXTC icon
76
NextCure
NXTC
$20.5M
$429K 0.12%
1,667
– –
ETNB
77
DELISTED
89bio
ETNB
$408K 0.12%
+20,478
New +$498K
PRVB
78
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$353K 0.1%
+25,000
New +$316K
GRTS
79
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$332K 0.1%
50,000
– –
RDUS
80
DELISTED
Radius Health, Inc.
RDUS
$300K 0.09%
22,000
– –
RIGL icon
81
Rigel Pharmaceuticals
RIGL
$726M
$289K 0.08%
15,770
– –
MREO
82
Mereo BioPharma
MREO
$47.9M
$235K 0.07%
+76,800
New +$135K
LITS
83
Lite Strategy Inc
LITS
$32.2M
$227K 0.07%
+2,750
New +$167K
ASLN
84
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$172K 0.05%
2,152
– –
LCTX icon
85
Lineage Cell Therapeutics
LCTX
$287M
$83K 0.02%
95,000
– –
CTMX icon
86
CytomX Therapeutics
CTMX
$734M
$51K 0.01%
6,100
-93,900
-94% -$872K
ARGX icon
87
argenx
ARGX
$54.3B
– –
-4,471
Closed -$589K
BTAI icon
88
BioXcel Therapeutics
BTAI
$25.2M
– –
-288
Closed -$103K
MGNX icon
89
MacroGenics
MGNX
$248M
– –
-150,000
Closed -$873K
SPRO icon
90
Spero Therapeutics
SPRO
$73M
– –
-48,103
Closed -$389K
URGN icon
91
UroGen Pharma
URGN
$2.27B
– –
-2,369
Closed -$42K
XCUR icon
92
Exicure
XCUR
$8.54M
– –
-1,833
Closed -$407K
ELOX
93
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
– –
-4,787
Closed -$375K
EPZM
94
DELISTED
Epizyme, Inc
EPZM
– –
-105,900
Closed -$1.64M
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q2 2020 Portfolio in Review

As of Q2 2020, DAFNA Capital Management held 95 positions worth $347M, up 45% from $240M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

DAFNA Capital Management's Q2 2020 filing shows 16 new, 11 increased, 34 reduced and 8 closed positions. Its largest new stake was Immunomedics Inc: 250,905 shares worth $8.89M. The largest sale was AtriCure, an estimated $4.64M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 92% a quarter earlier, followed by Financials.

  • DAFNA Capital Management's largest Q2 2020 buy was Immunomedics Inc: 250,905 shares worth $8.89M.
  • DAFNA Capital Management added most to Dicerna Pharmaceuticals, Inc. in Q2 2020, an estimated $6.6M increase.
  • DAFNA Capital Management's biggest Q2 2020 reduction was AtriCure, cutting an estimated $4.64M.
  • DAFNA Capital Management fully exited Epizyme, Inc in Q2 2020, selling an estimated $1.64M.
  • DAFNA Capital Management's ten largest holdings make up 49% of its $347M portfolio in Q2 2020.
  • DAFNA Capital Management opened 16 new positions and closed 8 in Q2 2020.
  • DAFNA Capital Management's portfolio value rose 45% quarter-over-quarter to $347M.

Based on DAFNA Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.